secwatch.observer — SEC 8-K summary
======================================

Issuer:     OS Therapies Inc (OSTX)
CIK:        0001795091
Form:       8-K
Filed at:   2025-01-29T23:59:59+00:00
Accession:  0001213900-25-007705
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 3.02, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OS Therapies acquires Ayala's listeria IP for $8M, eliminates milestones, adds Phase 2 lung asset
--------------------------------------------------------------------------------

- Total consideration $8M: $0.5M cash + $7.5M in OSTX shares; 180-day lock-up. Closes ~60 days.
- Eliminates $3.5M BLA milestone and $16.5M in OST-HER2 sales milestones; royalty reduced from 10% to 1.5% under Penn License.
- Adds Phase 2 ADXS-503 (NSCLC) and Phase 1 ADXS-504 (prostate) programs using Listeria monocytogenes platform.
- Karim Galzahr appointed to board; managing partner at OKG Capital, over 30 yrs finance experience.
- Company has $7.1M financing at $4/share; cash runway into 2026; no equity raises below $12 for 6 months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1795091/000121390025007705/0001213900-25-007705-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1795091/000121390025007705/ea0229055-8k_osthera.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-007705

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer